• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    CalciMedica Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/14/25 7:30:09 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CALC alert in real time by email
    8-K
    0001534133false00015341332025-05-142025-05-14

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 14, 2025

     

     

    CalciMedica, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-39538

    45-2120079

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    505 Coast Boulevard South, Suite 307

     

    La Jolla, California

     

    92037

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (858) 952-5500

     

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.0001 per share

     

    CALC

     

    The Nasdaq Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02. Results of Operations and Financial Condition.

     

    On May 14, 2025 CalciMedica, Inc. issued a press release announcing its financial results for the fiscal quarter ended March 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this report.

    The information in this Item 2.02, including Exhibit 99.1 to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits

    Exhibit

    Number

    Description

    99.1

    Press Release dated May 14, 2025

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    CalciMedica, Inc.

     

     

     

     

    Date:

    May 14, 2025

    By:

    /s/ A. Rachel Leheny, Ph. D.

     

     

    Name:

    Title:

    A. Rachel Leheny, Ph. D.
    Chief Executive Officer
     

     


    Get the next $CALC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CALC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CALC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

      Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Presentations at three recent medical meetings, including a post-hoc analysis of subset of patients with AKI in the Phase 2 CARDEA trial of Auxora in severe COVID-19 pneumonia, which showed a 62.7% relative reduction in mortality for Auxora versus placebo Cash position expected to fund operations into mid-2026 LA JOLLA, Calif., May 14, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition

      5/14/25 7:00:00 AM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CalciMedica Announces Presentations at Upcoming Medical Meetings

      LA JOLLA, Calif., April 17, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the acceptance of an abstract for poster presentation at Digestive Disease Week (DDW) 2025 being held May 3-6 in San Diego, CA, and the participation of Sudarshan Hebbar, M.D., Chief Medical Officer of CalciMedica, in both an oral presentation and a panel discussion at the American Society of Nephrology (ASN) 3rd Acute Kidney Injury: From Bench to Bedside Conferenc

      4/17/25 7:00:00 AM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CalciMedica to Participate in the Jones Healthcare and Technology Innovation Conference

      LA JOLLA, Calif., April 1, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will present at the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025, at 11:00 a.m. PT. A live webcast of the presentation can be accessed in the "Upcoming Events" se

      4/1/25 7:00:00 AM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Middleton Fred A bought $12,720 worth of shares (4,800 units at $2.65), increasing direct ownership by 15% to 36,514 units (SEC Form 4)

      4 - CalciMedica, Inc. (0001534133) (Issuer)

      12/6/24 7:12:27 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: CHIEF BUSINESS OFFICER Roberts Eric W bought $8,040 worth of shares (3,000 units at $2.68) (SEC Form 4)

      4/A - CalciMedica, Inc. (0001534133) (Issuer)

      11/6/24 8:00:07 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Sanderling Venture Partners Vi Co Investment Fund Lp bought $329,040 worth of shares (87,744 units at $3.75), increasing direct ownership by 12% to 814,300 units (SEC Form 4)

      4 - CalciMedica, Inc. (0001534133) (Issuer)

      11/5/24 3:08:23 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Bardin Stephen

      4 - CalciMedica, Inc. (0001534133) (Issuer)

      4/25/25 4:35:02 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Scientific Officer Stauderman Kenneth A.

      4 - CalciMedica, Inc. (0001534133) (Issuer)

      4/25/25 4:34:05 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by President and COO Dunn Michael J.

      4 - CalciMedica, Inc. (0001534133) (Issuer)

      4/25/25 4:33:07 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by CalciMedica Inc.

      SC 13D - CalciMedica, Inc. (0001534133) (Subject)

      11/26/24 6:03:55 AM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CalciMedica Inc.

      SC 13G/A - CalciMedica, Inc. (0001534133) (Subject)

      11/14/24 3:32:39 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CalciMedica Inc.

      SC 13G/A - CalciMedica, Inc. (0001534133) (Subject)

      11/14/24 1:05:20 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALC
    Financials

    Live finance-specific insights

    See more
    • CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

      Statistically significant 100% reduction (p = 0.0027) in new-onset severe respiratory failure and 64.2% reduction (p = 0.0476) in new-onset persistent respiratory failure in combined high and medium dose Auxora patients versus combined low dose Auxora and placebo patients Statistically significant stratified win ratio of 1.640 (p = 0.0372) for high dose Auxora compared to placebo Clinically meaningful reduction observed for high dose Auxora patients compared to placebo in additional key endpoints: new-onset necrotizing pancreatitis and time to medically indicated discharge Conference call and webcast to review full data set from the Ph2b CARPO trial to be held at 12 p.m. ET/ 9 a.m. PT LA JOL

      10/30/24 7:00:00 AM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

      Conference call and webcast to be held Wednesday, October 30, 2024 at 12 p.m. ET/ 9 a.m. PT LA JOLLA, Calif., Oct. 28, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that it will host a call on Wednesday, October 30, 2024 at 12 p.m. ET/ 9 a.m. PT to review the full data set and win ratio analysis from the Company's Phase 2b CARPO trial of Auxora™ in acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS). Prof. Robert Sutt

      10/28/24 4:05:00 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

      Positive topline data announced from CARPO, Phase 2b trial of Auxora™ in acute pancreatitis (AP); additional data to be presented at a medical meeting later this year First patient enrolled in KOURAGE, Phase 2 trial of Auxora™ in severe acute kidney injury (AKI), with data expected in 2025 LA JOLLA, Calif., Aug. 12, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica or the Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the second quarter ended June 30, 2024.

      8/12/24 4:10:00 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALC
    SEC Filings

    See more
    • SEC Form 10-Q filed by CalciMedica Inc.

      10-Q - CalciMedica, Inc. (0001534133) (Filer)

      5/14/25 4:15:43 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by CalciMedica Inc.

      SCHEDULE 13G/A - CalciMedica, Inc. (0001534133) (Subject)

      5/14/25 4:07:12 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CalciMedica Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CalciMedica, Inc. (0001534133) (Filer)

      5/14/25 7:30:09 AM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALC
    Leadership Updates

    Live Leadership Updates

    See more
    • CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

      Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Presentations at three recent medical meetings, including a post-hoc analysis of subset of patients with AKI in the Phase 2 CARDEA trial of Auxora in severe COVID-19 pneumonia, which showed a 62.7% relative reduction in mortality for Auxora versus placebo Cash position expected to fund operations into mid-2026 LA JOLLA, Calif., May 14, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition

      5/14/25 7:00:00 AM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates

      Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Post-hoc analysis of subset of patients with AKI in the Phase 2 CARDEA trial of Auxora in severe COVID-19 pneumonia showed a 62.7% relative reduction in mortality at day 30, which persisted through day 60, for patients treated with Auxora versus placebo Cash position expected to fund operations into mid-2026 LA JOLLA, Calif., March 27, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition

      3/27/25 7:00:00 AM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors

      LA JOLLA, Calif., Jan. 14, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the appointment of Alan Glicklich, M.D. to the Company's Board of Directors effective on January 15, 2025. Dr. Glicklich has more than 20 years of experience in the biotechnology industry and currently serves as Chief Medical Officer of Nuvig Therapeutics.

      1/14/25 7:00:00 AM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care